Terms of Use

Please read and accept the following terms before accessing this cBioPortal instance.

This portal contains genomic alteration data from whole genome and transcriptome sequencing of advanced cancers from the Personalized OncoGenomics (POG) Program, of the Genome Sciences Centre, PHSA, BC Cancer and the MoHCCN.

Please adhere to the Terms of Use, and cite Pleasance, Bohm et al, Annals of Oncology 2022 or Pleasance, Titmuss, Williamson et al, Nature Cancer 2020.

By accessing and downloading the somatic data made available via this cBioPortal instance by the Personalized OncoGenomics (POG) program, the user agrees to the following terms of use:

Failure to comply with any of the terms specified here may result in disqualification of the recipient from receiving additional data. PHSA shall have the right to institute and prosecute any proceeding at law or in equity against the recipient for violating or threatening to violate the confidentiality requirements of these terms, the limitations on the use of the data provided, or both. Proceedings may be initiated against the violating party, legal representatives, and assigns, for a restraining injunction, compensatory and punitive damages, mandamus, and/or any other proceeding in law or equity, including obtaining the proceeds from any intellectual property or other rights that are derived in whole or in part from the breach of the confidentiality requirements or use limitations of these terms. In addition, the recipient acknowledges and agrees that a breach or threatened breach of the confidentiality requirements or use limitations of these terms may subject the recipient to legal action on the part of study participants, their families, or both.

Anyone is free to copy, display, and make derivative data sets with this data for research purposes.

The POG program and funders must be acknowledged when publishing or presenting work using or referencing the POG dataset accessed here. The following sample text has been provided:

"This work would not be possible without the participation of our patients and families, the POG team, the GSC platform, and the generous support of the BC Cancer Foundation, Genome British Columbia (project B20POG, MOH001, MOH002), and the Terry Fox Research Institute Marathon of Hope Cancer Centres Network. We also acknowledge contributions towards equipment and infrastructure from Genome Canada and Genome BC (projects 202SEQ, 212SEQ, 262SEQ, 12002), Canada Foundation for Innovation (projects 20070, 30981, 30198, 33408, 35444, 42362, 40104, 43409) and the BC Knowledge Development Fund. Other contributors include Roche Pharma. The results published here are in part based upon data generated by the following projects and obtained from dbGaP (http://www.ncbi.nlm.nih.gov/gap): The Cancer Genome Atlas managed by the NCI and NHGRI (http://cancergenome.nih.gov); Genotype-Tissue Expression (GTEx) Project, supported by the Common Fund of the Office of the Director of the National Institutes of Health (https://commonfund.nih.gov/GTEx)."

I Accept